PRUNUS Therapeutics is a Chicagoland-based biotech startup launched in 2016. PRUNUS’ main platform focuses on sustainable cancer therapeutics based on its proprietary AcK-Lock prodrug technology. AcK-Lock is a molecular lock designed to selectively release active agents in a wide range of cancer cells, while protecting healthy cells from off-target effects. PRUNUS' pipeline products include small molecules, targeted protein/RNA degraders, biologics, vaccines, and companion diagnostic tests.

Our vision is to promote sustainable healthcare options for anyone in need to get back to normal life.                                                                                                   

Nobu Ueki, PhD (CEO and Founder) via LinkedIn

PRUNUS is developing new therapeutic approaches that may dramatically improve treatment outcome and quality of life by harnessing the body’s natural defense system.